Literature DB >> 33491714

Radiolabelling of nanomaterials for medical imaging and therapy.

Juan Pellico1, Peter J Gawne, Rafael T M de Rosales.   

Abstract

Nanomaterials offer unique physical, chemical and biological properties of interest for medical imaging and therapy. Over the last two decades, there has been an increasing effort to translate nanomaterial-based medicinal products (so-called nanomedicines) into clinical practice and, although multiple nanoparticle-based formulations are clinically available, there is still a disparity between the number of pre-clinical products and those that reach clinical approval. To facilitate the efficient clinical translation of nanomedicinal-drugs, it is important to study their whole-body biodistribution and pharmacokinetics from the early stages of their development. Integrating this knowledge with that of their therapeutic profile and/or toxicity should provide a powerful combination to efficiently inform nanomedicine trials and allow early selection of the most promising candidates. In this context, radiolabelling nanomaterials allows whole-body and non-invasive in vivo tracking by the sensitive clinical imaging techniques positron emission tomography (PET), and single photon emission computed tomography (SPECT). Furthermore, certain radionuclides with specific nuclear emissions can elicit therapeutic effects by themselves, leading to radionuclide-based therapy. To ensure robust information during the development of nanomaterials for PET/SPECT imaging and/or radionuclide therapy, selection of the most appropriate radiolabelling method and knowledge of its limitations are critical. Different radiolabelling strategies are available depending on the type of material, the radionuclide and/or the final application. In this review we describe the different radiolabelling strategies currently available, with a critical vision over their advantages and disadvantages. The final aim is to review the most relevant and up-to-date knowledge available in this field, and support the efficient clinical translation of future nanomedicinal products for in vivo imaging and/or therapy.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33491714     DOI: 10.1039/d0cs00384k

Source DB:  PubMed          Journal:  Chem Soc Rev        ISSN: 0306-0012            Impact factor:   54.564


  21 in total

Review 1.  A review of advances in the last decade on targeted cancer therapy using 177Lu: focusing on 177Lu produced by the direct neutron activation route.

Authors:  Rubel Chakravarty; Sudipta Chakraborty
Journal:  Am J Nucl Med Mol Imaging       Date:  2021-12-15

2.  Antitumor Activity of α-Linolenic Acid-Paclitaxel Conjugate Nanoparticles: In vitro and in vivo.

Authors:  Mei-Qi Xu; Yan-Li Hao; Jing-Ru Wang; Zhuo-Yue Li; Hui Li; Zhen-Han Feng; Hui Wang; Jing-Wen Wang; Xuan Zhang
Journal:  Int J Nanomedicine       Date:  2021-10-27

Review 3.  Nanomaterial Probes for Nuclear Imaging.

Authors:  Vanessa Jing Xin Phua; Chang-Tong Yang; Bin Xia; Sean Xuexian Yan; Jiang Liu; Swee Eng Aw; Tao He; David Chee Eng Ng
Journal:  Nanomaterials (Basel)       Date:  2022-02-09       Impact factor: 5.076

4.  Biodistribution of 68/67Ga-Radiolabeled Sphingolipid Nanoemulsions by PET and SPECT Imaging.

Authors:  Sandra Díez-Villares; Juan Pellico; Noemí Gómez-Lado; Santiago Grijalvo; Sandra Alijas; Ramon Eritja; Fernando Herranz; Pablo Aguiar; María de la Fuente
Journal:  Int J Nanomedicine       Date:  2021-08-26

Review 5.  Recent Advances in Brachytherapy Using Radioactive Nanoparticles: An Alternative to Seed-Based Brachytherapy.

Authors:  Baljeet Seniwal; Velaphi C Thipe; Sukhvir Singh; Telma C F Fonseca; Lucas Freitas de Freitas
Journal:  Front Oncol       Date:  2021-11-24       Impact factor: 6.244

Review 6.  Nanostructures as Radionuclide Carriers in Auger Electron Therapy.

Authors:  Nasrin Abbasi Gharibkandi; Joanna Gierałtowska; Kamil Wawrowicz; Aleksander Bilewicz
Journal:  Materials (Basel)       Date:  2022-02-01       Impact factor: 3.623

7.  Self-assembly of Peptide dendrimers and their bio-applications in theranostics.

Authors:  Fengjuan Xie; Rongxin Li; Weikang Shu; Liang Zhao; Jingjing Wan
Journal:  Mater Today Bio       Date:  2022-03-08

8.  Effect of XlogP and hansen solubility parameters on the prediction of small molecule modified docetaxel, doxorubicin and irinotecan conjugates forming stable nanoparticles.

Authors:  Mei-Qi Xu; Ting Zhong; Xin Yao; Zhuo-Yue Li; Hui Li; Jing-Ru Wang; Zhen-Han Feng; Xuan Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

9.  Biodistribution of Mesoporous Carbon Nanoparticles via Technetium-99m Radiolabelling after Oral Administration to Mice.

Authors:  Maria Mamai; Dimitra Giasafaki; Evangelia-Alexandra Salvanou; Georgia Charalambopoulou; Theodore Steriotis; Penelope Bouziotis
Journal:  Nanomaterials (Basel)       Date:  2021-11-30       Impact factor: 5.076

10.  Radiolabeled Gold Nanoseeds Decorated with Substance P Peptides: Synthesis, Characterization and In Vitro Evaluation in Glioblastoma Cellular Models.

Authors:  Francisco Silva; Alice D'Onofrio; Carolina Mendes; Catarina Pinto; Ana Marques; Maria Paula Cabral Campello; Maria Cristina Oliveira; Paula Raposinho; Ana Belchior; Salvatore Di Maria; Fernanda Marques; Carla Cruz; Josué Carvalho; António Paulo
Journal:  Int J Mol Sci       Date:  2022-01-06       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.